Published in Lancet Oncol on December 01, 2002
Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA. Nucleic Acids Res (2006) 1.17
Cancer biomarkers: are we ready for the prime time? Cancers (Basel) (2010) 1.10
DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn (2009) 1.08
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 1.06
Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases. Breast Cancer Res (2012) 1.05
Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res (2008) 1.02
Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics (2013) 0.96
Phenotype-specific CpG island methylation events in a murine model of prostate cancer. Cancer Res (2008) 0.95
Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem (2009) 0.95
Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling. Cancer Epidemiol Biomarkers Prev (2012) 0.94
Base-resolution methylation patterns accurately predict transcription factor bindings in vivo. Nucleic Acids Res (2015) 0.92
Targeting the epigenome with bioactive food components for cancer prevention. J Nutrigenet Nutrigenomics (2012) 0.91
The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. World J Surg Oncol (2009) 0.89
The Role of Extracellular Vesicles: An Epigenetic View of the Cancer Microenvironment. Biomed Res Int (2015) 0.86
Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol (2007) 0.86
Epigenetic Contributions to the Relationship between Cancer and Dietary Intake of Nutrients, Bioactive Food Components, and Environmental Toxicants. Front Genet (2012) 0.82
Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation. Anal Chem (2008) 0.82
G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer? Toxins (Basel) (2015) 0.79
Epigenetic research in cancer epidemiology: trends, opportunities, and challenges. Cancer Epidemiol Biomarkers Prev (2013) 0.78
Epigenetic modifications of caveolae associated proteins in health and disease. BMC Genet (2015) 0.77
Cytosine methyltransferases as tumor markers. Curr Genomics (2010) 0.76
Versatile Functions of Caveolin-1 in Aging-related Diseases. Chonnam Med J (2017) 0.75
Perspectives on personalized cancer care. Urol Oncol (2012) 0.75
Gastric cancer development after the successful eradication of Helicobacter pylori. World J Gastrointest Oncol (2016) 0.75
Role of several histone lysine methyltransferases in tumor development. Biomed Rep (2016) 0.75
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
A compendium of potential biomarkers of pancreatic cancer. PLoS Med (2009) 3.00
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
The human proteome project: current state and future direction. Mol Cell Proteomics (2011) 2.34
Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Proteomics for cancer biomarker discovery. Clin Chem (2002) 1.57
Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer (2005) 1.51
The word "cancer": how language can corrupt thought. BMJ (2013) 1.51
Challenges for biomarkers in cancer detection. Ann N Y Acad Sci (2004) 1.38
Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics (2006) 1.24
Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov Today (2005) 1.23
Results of the prospective multicenter trial of robotically assisted totally endoscopic coronary artery bypass grafting. Ann Thorac Surg (2006) 1.21
Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res (2007) 1.21
Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers (2004) 1.18
Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. Am J Clin Pathol (2008) 1.15
Biomarkers for prostate cancer detection. J Urol (2007) 1.14
Mitochondrial DNA as a cancer biomarker. J Mol Diagn (2005) 1.11
Early detection of sporadic pancreatic cancer: summative review. Pancreas (2015) 1.10
Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells. BMC Cancer (2009) 1.07
The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers. Clin Chem (2012) 1.05
Proteomic analysis of cancer-cell mitochondria. Nat Rev Cancer (2003) 1.05
New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res (2003) 1.02
Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer (2008) 1.02
The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark (2008) 1.01
Evaluation of anti-ulcerogenic and ulcer-healing properties of Ocimum sanctum Linn. J Ethnopharmacol (2004) 1.01
Multiple strand displacement amplification of mitochondrial DNA from clinical samples. BMC Med Genet (2008) 1.00
The promise of biomarkers in cancer screening and detection. Trends Mol Med (2002) 0.99
The human proteome project: Current state and future direction. Mol Cell Proteomics (2011) 0.96
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. J Proteomics (2012) 0.96
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urol Oncol (2004) 0.95
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. J Proteome Res (2013) 0.94
Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis (2012) 0.92
New paradigms in translational science research in cancer biomarkers. Transl Res (2012) 0.92
Epigenetics and cancer. Crit Rev Clin Lab Sci (2004) 0.91
Long-gradient separations coupled with selected reaction monitoring for highly sensitive, large scale targeted protein quantification in a single analysis. Anal Chem (2013) 0.90
Biomarkers in molecular medicine: cancer detection and diagnosis. Biotechniques (2005) 0.90
Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev (2006) 0.90
Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark (2007) 0.87
Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0. BMC Cancer (2008) 0.86
Immobilization strategies for single-chain antibody microarrays. Proteomics (2008) 0.86
Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection. Int J Cancer (2008) 0.86
The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark (2010) 0.86
Mitochondria as a target for early detection and diagnosis of cancer. Crit Rev Clin Lab Sci (2005) 0.86
ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity. Monoclon Antib Immunodiagn Immunother (2014) 0.81
Cancer biomarkers: an emerging means of detecting, diagnosing and treating cancer. Cancer Biomark (2005) 0.81
Biomarkers in oncology research and treatment: early detection research network: a collaborative approach. Biomark Med (2008) 0.80
Chemical constituents and antifilarial activity of Lantana camara against human lymphatic filariid Brugia malayi and rodent filariid Acanthocheilonema viteae maintained in rodent hosts. Parasitol Res (2006) 0.80
Molecular diagnostics: a new frontier in cancer prevention. Expert Rev Mol Diagn (2004) 0.79
The promise of biomarkers in colorectal cancer detection. Dis Markers (2004) 0.79
High-throughput analysis of telomerase by capillary electrophoresis. Electrophoresis (2003) 0.79
Translational pathology of neoplasia. Cancer Biomark (2010) 0.79
Nanotechnology in early detection of cancer. Lab Invest (2002) 0.78
Move over proteomics, here comes glycomics. J Proteome Res (2008) 0.78
Developing recombinant antibodies for biomarker detection. Cancer Biomark (2010) 0.77
Biomarkers for cancer diagnosis: implications for nutritional research. J Nutr (2004) 0.77
Strategic approach to validating methylated genes as biomarkers for breast cancer. Cancer Prev Res (Phila) (2010) 0.77
Cancer biomarkers: an emerging means of detecting, diagnosing and treating cancer. Dis Markers (2005) 0.77
Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells. J Mol Diagn (2004) 0.77
Wuchereria bancrofti: effect of single and multiple larval inoculations on infection dynamics and development of clinical manifestations in non-human primate Presbytis entellus. Exp Parasitol (2006) 0.77
Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report. Pancreas (2003) 0.76
A simple packed bed device for antibody labelled rare cell capture from whole blood. Lab Chip (2012) 0.76
Data standards for proteomics: mitochondrial two-dimensional polyacrylamide gel electrophoresis data as a model system. Mitochondrion (2004) 0.76
Preparation and characterization of candidate reference materials for telomerase assays. Clin Chem (2005) 0.76
Murine infection model for Mycobacterium fortuitum. Microbes Infect (2005) 0.76
Early Detection of Pancreatic Cancer-a Defined Future Using Lessons From Other Cancers: A White Paper. Pancreas (2016) 0.75
Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. Pancreas (2016) 0.75
Standards for immunohistochemical imaging: a protein reference device for biomarker quantitation. J Histochem Cytochem (2010) 0.75
A vanishing lesion. JACC Cardiovasc Interv (2010) 0.75
Biomarkers in public health. Cancer Biomark (2012) 0.75
Cancer biomarkers. Preface. Cancer Biomark (2005) 0.75
Noncoding RNAs in molecular characterization of cancer preneoplasia. Cancer Biomark (2010) 0.75
Cancer genetics in the post genomic era. Curr Mol Med (2007) 0.75
Standards in molecular diagnostics for the discovery and validation of clinically useful cancer biomarkers. Expert Rev Mol Diagn (2013) 0.75
Translational pathology of early cancer. Cancer Biomark (2010) 0.75
Proteomics in diagnostics. Dis Markers (2004) 0.75
Detecting role of apoptosis in mediating cyclophosphamide induced teratogenesis in vitro. Toxicol Mech Methods (2005) 0.75